Lumakras (sotorasib)

News alerts, weekly reports and conference planners

Company:

Amgen, Roche

Drug class:

KRAS G12C inhibitor

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2	panitumumab + sotorasib Sensitive: A2 - Guideline panitumumab + sotorasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2	cetuximab + sotorasib Sensitive: A2 - Guideline cetuximab + sotorasib Sensitive : A2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: B - Late Trials panitumumab + sotorasib Sensitive : B	panitumumab + sotorasib Sensitive: B - Late Trials panitumumab + sotorasib Sensitive : B
KRAS G12C + KEAP1 mutation	Non Small Cell Lung Cancer	KRAS G12C + KEAP1 mutation	Non Small Cell Lung Cancer	sotorasib Resistant: B - Late Trials sotorasib Resistant : B	sotorasib Resistant: B - Late Trials sotorasib Resistant : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B
KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B
KRAS G12C + TP53 mutation	Non Small Cell Lung Cancer	KRAS G12C + TP53 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Melanoma	KRAS G12C	Melanoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Lung Adenocarcinoma	KRAS G12C	Lung Adenocarcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib + AbGn-107 Sensitive: C3 – Early Trials sotorasib + AbGn-107 Sensitive : C3	sotorasib + AbGn-107 Sensitive: C3 – Early Trials sotorasib + AbGn-107 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 Sensitive: C3 – Early Trials sotorasib + VS-6766 Sensitive : C3	sotorasib + VS-6766 Sensitive: C3 – Early Trials sotorasib + VS-6766 Sensitive : C3
KRAS G12C + PD-L1 underexpression	Non Small Cell Lung Cancer	KRAS G12C + PD-L1 underexpression	Non Small Cell Lung Cancer	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3
KRAS G12C + PD-L1 underexpression + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + PD-L1 underexpression + STK11 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3	sotorasib Sensitive: C3 – Early Trials sotorasib Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	pembrolizumab + sotorasib Sensitive: C3 – Early Trials pembrolizumab + sotorasib Sensitive : C3	pembrolizumab + sotorasib Sensitive: C3 – Early Trials pembrolizumab + sotorasib Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	atezolizumab + sotorasib Sensitive: C3 – Early Trials atezolizumab + sotorasib Sensitive : C3	atezolizumab + sotorasib Sensitive: C3 – Early Trials atezolizumab + sotorasib Sensitive : C3
STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer	STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3
KRAS G12C + PD-L1 expression	Non Small Cell Lung Cancer	KRAS G12C + PD-L1 expression	Non Small Cell Lung Cancer	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3	sotorasib Resistant: C3 – Early Trials sotorasib Resistant : C3
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D

Lumakras (sotorasib)

Associations
(76)

Associations
(76)

Lumakras (sotorasib)

Associations(76)

Associations(76)

Associations
(76)

Associations
(76)